mlt004

Mark L. Tykocinski, MD

Contact Dr. Tykocinski

1025 Walnut Street
College Room 100
Philadelphia, PA 19107

(215) 955-1628

Most Recent Peer-reviewed Publications

  1. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells
  2. Cell Membrane Biology and Juxtacrine Signal Conversion
  3. Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth
  4. Signal Converter Proteins
  5. Energy transfer in "parasitic" cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells
  6. Inhibition of effector function but not T cell activation and increase in FoxP3 expression in T cells differentiated in the presence of PP14
  7. CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling
  8. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis
  9. CTLA-4·Ig converts naive CD4+ CD25- T cells into CD4+CD25+ regulatory T cells
  10. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
  11. CTLA-4·FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals
  12. OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-κB binding sites
  13. CD40·FasL inhibits human T cells: Evidence for an auto-inhibitory loop-back mechanism
  14. α2,6-Sialylation promotes binding of placental protein 14 via its Ca2+-dependent lectin activity: Insights into differential effects on CD45RO and CD45RA T cells
  15. CTLA-4·FasL inhibits allogeneic responses in vivo
  16. Pathology as the enabler of human research
  17. Pregnancy zone protein is a carrier and modulator of placental protein-14 in T-cell growth and cytokine production
  18. Differential regulation of Th1/Th2 cytokine responses by placental protein 14
  19. New designs for cancer vaccine and artificial veto cells: An emerging palette of protein paints
  20. CTLA-4 · FasL induces alloantigen-specific hyporesponsiveness